Millennium Management LLC Has $4.86 Million Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Millennium Management LLC reduced its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 34.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,959,047 shares of the biotechnology company's stock after selling 1,046,551 shares during the quarter. Millennium Management LLC owned approximately 2.74% of Aclaris Therapeutics worth $4,858,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. ExodusPoint Capital Management LP bought a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $26,000. Invesco Ltd. bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $28,000. Graham Capital Management L.P. bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $35,000. Commonwealth Equity Services LLC bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $36,000. Finally, Alpine Global Management LLC bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $38,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Trading Down 1.4%

NASDAQ ACRS traded down $0.02 during midday trading on Monday, hitting $1.44. The company had a trading volume of 645,432 shares, compared to its average volume of 1,190,769. The company has a market capitalization of $155.92 million, a PE ratio of -2.77 and a beta of 0.42. The firm has a 50-day moving average price of $1.30 and a 200-day moving average price of $2.16. Aclaris Therapeutics, Inc. has a twelve month low of $0.99 and a twelve month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, equities analysts anticipate that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ACRS. Wedbush began coverage on Aclaris Therapeutics in a research note on Wednesday, May 28th. They issued an "outperform" rating and a $8.00 price target for the company. Scotiabank reduced their price target on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research note on Friday, May 9th. Cantor Fitzgerald began coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating for the company. Wall Street Zen downgraded Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective (down from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.71.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.